The Impact of Prior Antithrombotic use on Thromboembolic Events in Patients with Cardiovascular Disease and Severe COVID-19 Infection
Objective Our objective in this study was to determine the predictive factors of thromboembolic complications in patients with previous heart disease and severe covid-19 infection and the impact of previous use of antithrombotics on protection against these complications. Methods We conducted a sing...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-12-01
|
| Series: | Clinical and Applied Thrombosis/Hemostasis |
| Online Access: | https://doi.org/10.1177/10760296221141449 |
| _version_ | 1811177479799308288 |
|---|---|
| author | Amine Bouchlarhem MD Soumia Boulouiz MD Ghizlane el Aidouni PR Houssam Bkiyar PR Zakaria Bazid PR Nabila Ismaili PR Brahim Housni PR Noha El Ouafi PR |
| author_facet | Amine Bouchlarhem MD Soumia Boulouiz MD Ghizlane el Aidouni PR Houssam Bkiyar PR Zakaria Bazid PR Nabila Ismaili PR Brahim Housni PR Noha El Ouafi PR |
| author_sort | Amine Bouchlarhem MD |
| collection | DOAJ |
| description | Objective Our objective in this study was to determine the predictive factors of thromboembolic complications in patients with previous heart disease and severe covid-19 infection and the impact of previous use of antithrombotics on protection against these complications. Methods We conducted a single-center retrospective study of 158 patients with heart disease admitted to an intensive care unit for severe SARS-COV-2 infection. In order to determine the predictive factors, we used logistic regression analysis. Results Out of 158 patients, 22 were complicated by a thrombo-embolic event (13.9%), mean age of our population 64.03 (SD = 15.27), with a male predominance of 98 (62%). For the predictive factors of thromboembolic complications, and after multivariate analysis, we find the short duration of hospitalization (OR = 0.92; 95%CI (0.863–0.983), P = .014, previous use of antithrombotic drugs ((OR = 0.288, 95%CI (0.091–0.911), P = .034 for antiplatelet agents) and (OR = 0.322, 95% CI (0, 131–0.851), P = .021) for anticoagulants) as protective factors, and admission thrombocytosis as a risk factor (OR = 4.58, 95%CI (1.2–10.627), P = .021). D-dimer was not detected as a risk factor, and this can be explained by the characteristics of our population. Although prior use of antithrombotic drugs protects against thromboembolic complications during severe infection, there was no benefit in mortality. Conclusion Prior use of antithrombotic drugs is a protective factor against thromboembolic complications in patients with a history of heart disease but without effect on mortality. |
| first_indexed | 2024-04-11T06:02:32Z |
| format | Article |
| id | doaj.art-d2001b8530fb493b9d125b9217bd67d4 |
| institution | Directory Open Access Journal |
| issn | 1938-2723 |
| language | English |
| last_indexed | 2024-04-11T06:02:32Z |
| publishDate | 2022-12-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical and Applied Thrombosis/Hemostasis |
| spelling | doaj.art-d2001b8530fb493b9d125b9217bd67d42022-12-22T04:41:38ZengSAGE PublishingClinical and Applied Thrombosis/Hemostasis1938-27232022-12-012810.1177/10760296221141449The Impact of Prior Antithrombotic use on Thromboembolic Events in Patients with Cardiovascular Disease and Severe COVID-19 InfectionAmine Bouchlarhem MD0Soumia Boulouiz MD1Ghizlane el Aidouni PR2Houssam Bkiyar PR3Zakaria Bazid PR4Nabila Ismaili PR5Brahim Housni PR6Noha El Ouafi PR7 Department of Cardiology, Mohammed VI University Hospital Mohammed I University Oujda, Oujda, Morocco Department of Cardiology, Mohammed VI University Hospital Mohammed I University Oujda, Oujda, Morocco Department of Intensive Care unit, Mohammed VI University Hospital Mohammed I University Oujda, Oujda, Morocco Department of Intensive Care unit, Mohammed VI University Hospital Mohammed I University Oujda, Oujda, Morocco Department of Cardiology, Mohammed VI University Hospital Mohammed I University Oujda, Oujda, Morocco Department of Cardiology, Mohammed VI University Hospital Mohammed I University Oujda, Oujda, Morocco Department of Intensive Care unit, Mohammed VI University Hospital Mohammed I University Oujda, Oujda, Morocco Department of Epidemiology, Mohammed VI University Hospital Mohammed I University Oujda, Oujda, MoroccoObjective Our objective in this study was to determine the predictive factors of thromboembolic complications in patients with previous heart disease and severe covid-19 infection and the impact of previous use of antithrombotics on protection against these complications. Methods We conducted a single-center retrospective study of 158 patients with heart disease admitted to an intensive care unit for severe SARS-COV-2 infection. In order to determine the predictive factors, we used logistic regression analysis. Results Out of 158 patients, 22 were complicated by a thrombo-embolic event (13.9%), mean age of our population 64.03 (SD = 15.27), with a male predominance of 98 (62%). For the predictive factors of thromboembolic complications, and after multivariate analysis, we find the short duration of hospitalization (OR = 0.92; 95%CI (0.863–0.983), P = .014, previous use of antithrombotic drugs ((OR = 0.288, 95%CI (0.091–0.911), P = .034 for antiplatelet agents) and (OR = 0.322, 95% CI (0, 131–0.851), P = .021) for anticoagulants) as protective factors, and admission thrombocytosis as a risk factor (OR = 4.58, 95%CI (1.2–10.627), P = .021). D-dimer was not detected as a risk factor, and this can be explained by the characteristics of our population. Although prior use of antithrombotic drugs protects against thromboembolic complications during severe infection, there was no benefit in mortality. Conclusion Prior use of antithrombotic drugs is a protective factor against thromboembolic complications in patients with a history of heart disease but without effect on mortality.https://doi.org/10.1177/10760296221141449 |
| spellingShingle | Amine Bouchlarhem MD Soumia Boulouiz MD Ghizlane el Aidouni PR Houssam Bkiyar PR Zakaria Bazid PR Nabila Ismaili PR Brahim Housni PR Noha El Ouafi PR The Impact of Prior Antithrombotic use on Thromboembolic Events in Patients with Cardiovascular Disease and Severe COVID-19 Infection Clinical and Applied Thrombosis/Hemostasis |
| title | The Impact of Prior Antithrombotic use
on Thromboembolic Events in Patients
with Cardiovascular Disease and Severe COVID-19 Infection |
| title_full | The Impact of Prior Antithrombotic use
on Thromboembolic Events in Patients
with Cardiovascular Disease and Severe COVID-19 Infection |
| title_fullStr | The Impact of Prior Antithrombotic use
on Thromboembolic Events in Patients
with Cardiovascular Disease and Severe COVID-19 Infection |
| title_full_unstemmed | The Impact of Prior Antithrombotic use
on Thromboembolic Events in Patients
with Cardiovascular Disease and Severe COVID-19 Infection |
| title_short | The Impact of Prior Antithrombotic use
on Thromboembolic Events in Patients
with Cardiovascular Disease and Severe COVID-19 Infection |
| title_sort | impact of prior antithrombotic use on thromboembolic events in patients with cardiovascular disease and severe covid 19 infection |
| url | https://doi.org/10.1177/10760296221141449 |
| work_keys_str_mv | AT aminebouchlarhemmd theimpactofpriorantithromboticuseonthromboemboliceventsinpatientswithcardiovasculardiseaseandseverecovid19infection AT soumiaboulouizmd theimpactofpriorantithromboticuseonthromboemboliceventsinpatientswithcardiovasculardiseaseandseverecovid19infection AT ghizlaneelaidounipr theimpactofpriorantithromboticuseonthromboemboliceventsinpatientswithcardiovasculardiseaseandseverecovid19infection AT houssambkiyarpr theimpactofpriorantithromboticuseonthromboemboliceventsinpatientswithcardiovasculardiseaseandseverecovid19infection AT zakariabazidpr theimpactofpriorantithromboticuseonthromboemboliceventsinpatientswithcardiovasculardiseaseandseverecovid19infection AT nabilaismailipr theimpactofpriorantithromboticuseonthromboemboliceventsinpatientswithcardiovasculardiseaseandseverecovid19infection AT brahimhousnipr theimpactofpriorantithromboticuseonthromboemboliceventsinpatientswithcardiovasculardiseaseandseverecovid19infection AT nohaelouafipr theimpactofpriorantithromboticuseonthromboemboliceventsinpatientswithcardiovasculardiseaseandseverecovid19infection AT aminebouchlarhemmd impactofpriorantithromboticuseonthromboemboliceventsinpatientswithcardiovasculardiseaseandseverecovid19infection AT soumiaboulouizmd impactofpriorantithromboticuseonthromboemboliceventsinpatientswithcardiovasculardiseaseandseverecovid19infection AT ghizlaneelaidounipr impactofpriorantithromboticuseonthromboemboliceventsinpatientswithcardiovasculardiseaseandseverecovid19infection AT houssambkiyarpr impactofpriorantithromboticuseonthromboemboliceventsinpatientswithcardiovasculardiseaseandseverecovid19infection AT zakariabazidpr impactofpriorantithromboticuseonthromboemboliceventsinpatientswithcardiovasculardiseaseandseverecovid19infection AT nabilaismailipr impactofpriorantithromboticuseonthromboemboliceventsinpatientswithcardiovasculardiseaseandseverecovid19infection AT brahimhousnipr impactofpriorantithromboticuseonthromboemboliceventsinpatientswithcardiovasculardiseaseandseverecovid19infection AT nohaelouafipr impactofpriorantithromboticuseonthromboemboliceventsinpatientswithcardiovasculardiseaseandseverecovid19infection |